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Objectives: The purpose of this study is to investigate the anti-inflammatory activity
of a hexa-herbal Chinese formula (HHCF) using spontaneously immortalized human
epidermal keratinocytes (HaCaT) and to predict the active components by correlating
the LC-MS-based metabolite profiles of the HHCF and its 12 varied formulae with their
anti-inflammatory activity using partial least-squares regression analysis.
Methods: The HHCF comprises the rootstock of Scutellaria baicalensis, Rheum
tanguticum, Sophora flavescens, the root bark of Dictamnus dasycarpus, the bark
of Phellodendron chinense, and the fruit of Kochia scoparia in equal proportions. Its
12 varied formulae were developed by uniform design with varied proportions of the
component botanical drugs. The decoctions of the HHCF and its 12 varied formulae
were profiled using liquid chromatography (LC) combined with triple quadrupole mass
spectrometry (MS) and their effects on tumor necrosis factor (TNF)-α -plus-interferon
(IFN)-γ-induced C-C motif chemokine ligand 17 (CCL17) production in HaCaT were
investigated. Partial least-squares regression analysis was conducted to assess the
relationship between the LC-MS-based metabolite profiles of the decoctions to
anti-CCL17 production in HaCaT.
Results: Compounds with potential to promote anti-CCL17 production in HaCaT were
identified (e.g., berberine, pyrogallol and catechin dimers) as a result of the developed
model and their potential to act as anti-inflammatory agents were also supported by
relevant literature.
Conclusion: This promising approach should assist in the screening process of
active components from complex Chinese herbal preparations and will better inform the
necessary pharmacological experiments to take forward.
Keywords: CCL17, Chinese herbal medicine formula, chemometric, HaCaT, inflammation, LC-MS-based
metabolite profiles, partial least-squares regression
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INTRODUCTION
Chinese medicine views a disease condition as the result of
different syndromes and treats the diagnosed disorders using
a combination of botanical drugs—a formula that has been
optimized based on centuries of clinical experiences. The
formulae of Chinese herbal medicine (CHM) act as mixture-
based libraries for development of multicomponent therapeutic
agents that may interact favorably with multiple targets, to
achieve therapeutic effects with fewer side effects (Medina-
Franco et al., 2013; Koeberle andWerz, 2014). Instead of isolating
and testing pharmacological activities of individual chemical
components of a CHM drugs or formulae, here we use a strategy
in which we first want to understand the exact composition used
in one specific preparation (in this case an aqueous extract).
This strategy has been used far less commonly and offers the
opportunity to understand the composition and the effects of
the preparations used. Advancements in analytical techniques
open up the possibility of profiling a multitude of small molecule
metabolites in the complex CHM extracts. These fingerprints of
CHM extracts can potentially be used to assess the composition
of preparations and consistency of chemical constituents from
batch-to-batch extracts and to ensure reproducible clinical effects
by monitoring the bioactive components. Specifically, correlating
metabolites profiles of CHM formulae to their bioactive effects
using chemometrics has become an alternative approach to
investigate the bioactive ingredients of CHM (Xu et al., 2014).
For example, Wang et al. explored the bioactive components
of a CHM formula by analyzing the relationship between the
peaks area of prominent peaks in its HPLC fingerprints and
the biological effects in vivo (Wang et al., 2014). While Su
et al. explored the bioactive components of a CHM formula by
analysing the relationship between the peak areas of prominent
peaks in its GC fingerprints and the biological effects in vitro (Su
et al., 2008).
In the present work, a method of predicting the active
components in a Chinese herbal formula was used by correlating
the metabolites in the LC-MS-based metabolite profiles of
the Chinese herbal formula and related formulae to their
respective levels of in vitro activity using chemometrics. In
previous published works, only peak areas of characteristic
peaks were used as the independent variables in building
the multivariate regression models. Here, metabolites are
selected based on their ion intensity levels in the extracts in
descending order. Ion intensities of compounds in the LC-MS
fingerprints were used as the independent variables that are
more specific than peak areas in representing the metabolites in
the extracts. The specific preparation is a hexa-herbal Chinese
formula (HHCF) comprising rootstock of Scutellaria baicalensis
Georgi (Lamiaceae; SCU), Rheum tanguticum Maxim. ex Balf.
Abbreviations: CHM, Chinese herbal medicine; DIC, the root bark of Dictamnus
dasycarpus Turcz.; HaCaT, spontaneously immortalized human epidermal
keratinocytes; HHCF, hexa-herbal Chinese formula; KOC, the fruit of Kochia
scoparia (L.) Schrad.; PHE, the bark of Phellodendron chinensisC.K. Schneid.; PLS-
R, partial least-squares regression; RC, regression coefficient; RHE, the rootstock
of Rheum tanguticumMaxim. ex Balf.; SCU, the rootstock of Scutellaria baicalensis
Georgi; SOP, the rootstock of Sophora flavescens Aiton.
(Polygonaceae; RHE), Sophora flavescens Aiton (Fabaceae; SOP),
root bark of Dictamnus dasycarpus Turcz. (Rutaceae; DIC), bark
of Phellodendron chinense C. K. Schneid. (Rutaceae; PHE), and
fruit of Kochia scoparia (L.) Schrad. (Amaranthaceae; KOC). The
HHCF consists of four botanical drugs that are used in the “San
Huang Xi Ji” formula. “San Huang Xi Ji” is a skin wash prepared
by decocting equal amounts of PHE, RHE, SCU and SOP in water
and is indicated for inflammatory skin conditions associated with
pathogenic-heat, dampness and wind such as atopic dermatitis
(Liang, 1993). In the HHCF, DIC and KOC are added to the “San
Huang Xi Ji” formula in order to enhance the therapeutic effect.
The actions of each botanical drugs in the HHCF according to the
concepts of TCM are summarized in Table 1.
To explore the active components of the HHCF, the major
metabolites in the LC-MS-based metabolites profiles of the
HHCF and its 12 varied formulae decoctions were correlated with
their effects on TNF-α -plus-IFN-γ-induced CCL17 production
in HaCaT, using partial least-squares regression (PLS-R).
MATERIALS AND METHODS
Materials
All botanical drugs were purchased from commercial Chinese
herbal medicine stores in China. SCU, RHE, SOP, DIC, KOC,
TABLE 1 | Actions of botanical drugs in the HHCF.
Pattern Botanical drugs in the HHCF
Clearing heat and
dry-dampness
Dried rootstock of Sophora flavescens Aiton,
Dried rootstock of Scutellaria baicalensis Georgi
Dried bark of Phellodendron chinense C. K. Schneid.
Removing wind to stop
itchiness
Dried root bark of Dictamnus dasycarpus Turcz.
Dried fruit of Kochia scoparia (L.) Schrad.
Clearing heat and toxin Dried rootstock of Rheum tanguticum Maxim. Ex Balf.
Dried rootstock of Scutellaria baicalensis Georgi
Dried bark of Phellodendron chinense C. K. Schneid.
Dried root bark of Dictamnus dasycarpus Turcz.
TABLE 2 | Percentage of 6 botanical drugs in the 12 varied formulae of the HHCF
under uniform design.
SOP (%) SCU (%) PHE (%) RHE (%) DIC (%) KOC (%)
V1 47 17 12 4 1 19
V2 34 12 8 18 4 25
V3 27 6 1 53 3 11
V4 22 1 31 5 12 29
V5 18 33 9 13 10 17
V6 14 19 3 41 10 12
V7 12 10 39 3 20 17
V8 9 3 20 18 31 19
V9 7 51 3 21 13 5
V10 5 25 46 1 19 5
V11 3 14 23 13 42 6
V12 1 6 10 38 43 2
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FIGURE 1 | The schematic diagram of the proposed approach. N9, Nll, N13, N21 and N27, and P14, P16, PIS, P26, and P31 are the top 5 most abundant
metabolites in the HHCF in negative and positive ionization mode, respectively. Chemical structures of these metabolites are shown in Figure 2.
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TABLE 3A | Putatively identified compounds in the HHCF by LC-MS/MS in positive ionization mode.
Rt
(min)
No. m/z Adduct ion(s) Source Identity (CAS number)
3.36 P1 191 [M+H]+ SOP Cytisine (485-35-8)
P2 196 [M]+ PHE Atraric acid (4707-47-5)
P3 205 [M+H]+ SOP N-Methylcytisine (6220-47-9)
P4 215 [M]+ RHE Mecoprop (93-65-2)
P5 261 [M+H]+ SOP Baptifoline (732-50-3)
3.75 P6 265 [M+H]+ SOP 5α-Hydroxymatrine (3411-37-8)/9α-Hydroxymatrine (88509-92-6)
4.15 P7 265 [M+H]+ SOP 14β-Hydroxymatrine (183074-18-2)
4.40 P8 180 [M]+ PHE Candicine (6656-13-9)
4.75 P9 245 [M+H]+ SOP Anagyrine (486-89-5)
P10 265 [M+H]+ SOP 5α-Hydroxymatrine (3411-37-8)/9α-Hydroxymatrine (88509-92-6)
5.00 P11 247 [M+H]+ SOP Isosophocarpine (68398-59-4)
5.52 P12 263 [M+H]+ SOP (-)-9α-hydroxy-7, 11-dehydromatrine (1257392-34-9)
5.72 P13 192 [M+H]+ PHE Noroxyhydrastinine (21796-14-5)
P14 249 [M+H]+ SOP Allomatrine (641-39-4)/Isomatrine (17801-36-4)/Matrine
(519-02-8)/Sophoridine (6882-68-4)
6.47 P15 247 [M+H]+ SOP Sophocarpine (6483-15-4)
P16 249 [M+H]+ SOP Allomatrine (641-39-4)/Isomatrine (17801-36-4)/Matrine
(519-02-8)/Sophoridine (6882-68-4)
8.02 P17 263 [M+H]+ SOP Oxysophocarpine (26904-64-3)
P18 265 [M+H]+ SOP Oxymatrine (16837-52-8)/Oxysophoridine (1217501-78-4)
P19 266 [M+NH4]
+ SOP Lupanine (550-90-3)
10.42 P20 247 [M+H]+ SOP (+)-7,11-Dehydromatrine (46862-63-9)
11.30 P21 263 [M+H]+ SOP 9α-Hydroxysophocarpine (220961-52-4)
11.48 P22 263 [M+H]+ SOP Leontalbinine N-oxide (147731-96-2)
P23 265 [M+H]+ SOP Oxymatrine (16837-52-8)/Oxysophoridine (1217501-78-4)
11.88 P24 243 [M+H]+ / DIC Dasycarpusenester A (1419709-60-6)
[M]+ O-Ethylnor-γ-fagarine (105988-99-6)
16.77 P25 314 [M]+ PHE (-)-Oblongine (152230-57-4)
20.08 P26 342 [M+H]+ PHE Phellodendrine (6873-13-8)
22.08 P27 344 [M+H]+ PHE Tembetarine (18446-73-6)
22.91 P28 342 [M+H]+ PHE Magnoflorine (2141-09-5)
26.84 P29 314 [M+H]+ PHE Evoeuropine (524-20-9)
31.32 P30 356 [M+H]+ PHE Menisperine (25342-82-9)
52.87 P31 336 [M]+ PHE Berberine (2086-83-1)
and PHE were sourced from Hebei (Chengde), Gansu (Maqu
county), Hebei (Chengde), Liaoning (Anshan), Hebei (Chengde),
and Sichuan (Dujiangyan), respectively, and were authenticated
by the first author based on her experience with CHMs. Samples
were deposited at the School of Pharmacy Medicinal Plant
Herbarium and are numbered as JC1–6. MS grade formic acid
and LC-MS grade acetonitrile were obtained from Sigma-Aldrich
and LC-MS grade water was obtained from Fisher Scientific.
HaCaT were obtained from Cell Lines Service, Eppelheim,
Germany. Dulbecco’s modified Eagle medium (DMEM),
Ca2+ and Mg2+ -free phosphate buffer saline (PBS) and 100
U/mL penicillin and 100µg/mL streptomycin were obtained
from Gibco. 10% heat inactivated fetal bovine serum, DMSO
and 3-(4,5-dimethylthizaol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) were obtained from Sigma-Aldrich. Human
TNF-α and IFN-γ were obtained from Peprotech. The
human CCL17 DuoSet enzyme linked-immunosorbent
assay (ELISA) kit was obtained from R&D
Systems.
Preparation of the HHCF and the 12 Varied
Formulae Decoctions
All botanical drugs, except SCU, were blended into a powder
and SCU was cut into small blocks of 1 × 1 cm (powdered
SCU will result in a too viscous extract that cannot be filtered)
before the decoction process. For the HHCF decoction, the same
ratio of each botanical drug (i.e., SCU, RHE, SOP, DIC, PHE,
and KOC) was used. A six-factor, 12-level uniform design was
applied to establish differences among the 12 varied formulae of
the HHCF (i.e., V1-V12; Table 2). Table 2 was developed based
on the U12 (12
5) uniform deign table and method described in
Fang (1994).
For each formula, botanical drugs were first macerated in
distilled water (at a volume of 5 fold the dry weight of botanical
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TABLE 3B | Putatively identified compounds in the HHCF by LC-MS/MS in negative ionization mode.
Rt
(min)
No. m/z Adduct ion(s) Source Identity (CAS number)
2.34 N1 193 [M-H]− SCU Glucuronic acid (6556-12-3)
2.46 N2 191 [M-H]− PHE Quinic acid (77-95-2)
N3 223 [M-H]− SOP Sinapic acid (530-59-6)
3.50 N4 191 [M-H]− PHE Citric acid (77-92-9)
N5 331 [M-H]− RHE Galloylglucose [i.e., 1-O-Galloyl-β-D-glucose (13405-60-2) or
4.08 N6 331 [M-H]− RHE 6-O-Galloyl-β-D-glucose (34781-46-9)]/Glucopyranosyloxyl gallic acid [i.e. Gallic
4.61 N7 331 [M-H]− RHE acid-3-O-β-D-glucoside (91984-84-8) or Gallic acid-4-O-β-D-glucoside
(84274-52-2)]
5.35 N8 125 [M-H]− RHE Pyrogallol (87-66-1)
N9 169 [M-H]− RHE Gallic acid (149-91-7)
N10 331 [M-H]− RHE Galloylglucose [i.e. 1-O-Galloyl-β-D-glucose (13405-60-2) or
6-O-Galloyl-β-D-glucose (34781-46-9)]/Glucopyranosyloxyl gallic acid [i.e. Gallic
acid-3-O-β-D-glucoside (91984-84-8) or Gallic acid-4-O-β-D-glucoside
(84274-52-2)]
8.71 N11 255 [M-H]− SOP Piscidic acid (35388-57-9)
13.88 N12 577 [M-H]− RHE Procyanidin B (15514-06-4)
16.48 N13 289 [M-H]− RHE Catechin (154-23-4)
N14 353 [M-H]− PHE Chlorogenic acid (327-97-9)
18.15 N15 367 [M-H]− PHE 3-O-Feruloylquinic acid (1899-29-2)
21.10 N16 325 [M-H]− RHE 4-(4′-Hydroxylphenyl)-2-butanone 4′-O-β-D-glucoside (38963-94-9)
N17 415 [M+Na-2H]− RHE 6-Hydroxymusizin-8-O- β-D-glucoside(23566-96-3)
22.77 N18 289 [M-H]− RHE Epicatechin (490-46-0)
N19 337 [M-H]− PHE p-coumaroylquinic acid (87099-71-6/93451-44-6)
24.72 N20 303 [M-H]− SCU 2′,3,5,6′,7-Pentahydroxyflavanone (1402054-86-7/80366-15-0)
26.26 N21 367 [M-H]− PHE 5-O-Feruloylquinic acid (40242-06-6)
26.65 N22 389 [M-H]− RHE Resveratrol-4′-O-β-D-glucoside (38963-95-0)/Resveratrol 3-O-β-glucoside
(27208-80-6)
32.06 N23 301 [M-H]− SCU 3,5,7,2′,6′-Pentahydroxyflavone (92519-95-4)
34.57 N24 441 [M-H]− RHE Epicatechin 3-O-gallate (1257-08-5)
N25 477 [M-H]− RHE Isolindleyin (87075-18-1)
N26 547 [M-H]− SCU Chrysin-6-C-arabinosyl-8-C-glucoside (185145-33-9/ 1884390-97-9)
36.56 N27 477 [M-H]− RHE Lindleyin (59282-56-3)
N28 545 [M-H]− RHE Rhein-8-O-D-[6′-O-(3′′-methoxylmalonyl)] glucoside (1333328-11-2)
37.25 N29 547 [2M-H]− SCU Chrysin-6-C-glucosyl-8-C-arabonoside (185145-34-0/ 1884390-98-0)
38.43 N30 541 [M-H]− RHE Resveratrol-4′-O-β-D-(2′′-O-galloyl) glucoside (105304-51-6)
39.20 N31 541 [M-H]− RHE Resveratrol-4′-O-β-D-(6′′-O-galloyl) glucoside (64898-03-9)
45.08 N32 301 [M-H]− SCU Trihydroxy-methoxyflavanone (92519-96-5)
46.91 N33 431 [M-H]− RHE Emodin-1-O-β-D-glucoside (38840-23-2)/Emodin-8-O-β-D-glucoside
(23313-21-5)/Aloe-emodin 8-O-β-D-glucoside
(33037-46-6)/Aloe-emodin-3-CH2-O-β-D-glucoside (50488-89-6)
55.48 N34 481 [M+Cl]− SOP (-)-Maackiain-3-O-glucoside (6807-83-6)
58.94 N35 431 [M-H]− RHE Emodin-1-O-β-D-glucoside (38840-23-2)/Emodin-8-O-β-D-glucoside
(23313-21-5)/Aloe-emodin 8-O-β-D-glucoside
(33037-46-6)/Aloe-emodin-3-CH2-O-β-D-glucoside (50488-89-6)
63.95 N36 233 [M-H]− RHE (5Z)-6-Hydroxy-3,4-dioxo-6-phenyl-5-hexenoic acid (NA)
71.02 N37 269 [M-H]− SCU 5,6,7-Trihydroxyflavone (491-67-8) OR 5,7,8-Trihydroxyflavone (4443-09-8)
drug used) for 1 h and then heated under reflux for 95min. The
extracted solution was filtered through nylon cloth of pore size
∼0.1mm, followed by centrifugation at 10,000 rpm for 5min.
The collected supernatant was lyophilized.
LC-MS/MS Profiling of the HHCF and Its 12
Varied Formulae
Lyophilized decoctions of the HHCF and its 12 varied formulae
were dissolved in LC-MS grade water to achieve a concentration
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FIGURE 2 | The top 5 most abundant metabolites in the HHCF in positive and negative ionization mode.
of 20 mg/mL, centrifuged at 10,000 rpm for 10min and filtered
through 0.22µm filter membrane before analysis. They were
subsequently profiled by LC-MS using the method described in
the “LC-MS/MS analysis” section of the previous publication
(Chang et al., 2016).
Partial Least-Squares Regression (PLS-R)
Analysis
The abundance of major metabolites in the HHCF and its 12
varied formulae were used as the independent variables. The
reciprocal levels of CCL17 produced by HaCaT after treatment
with the HHCF and its 12 varied formulae at a concentration
of 60µg/mL were used as the dependent variables. At this
concentration, all tested samples demonstrated statistically
significant CCL17 inhibition in HaCaT stimulated with TNF-
α-plus-IFN-γ. The independent and dependent variables were
mean-centered and scaled and were subsequently imported to
JMP Pro 12 software from SAS to build the PLS-R model. Leave-
one-out cross validation was carried out to select the optimal
number of latent variables for the PLS-R analysis based on the
root-mean-square error of cross-validation (RMSECV) value.
Cell Culture
The HaCaT (Boukamp et al., 1988) were cultured in DMEM
containing 10% heat inactivated fetal bovine serum and 100
U/ml penicillin and 100µg/mL streptomycin, in 5% CO2 at 37
(Turksen, 2004).
Enzyme Linked Immunosorbent Assay
(ELISA)
HaCaT were seeded into a 96-well plate (200 µl per well of
2 × 104 cells/mL). After 24 h, the medium was replaced with
serum-free medium and cells were cultured for another 24 h.
The medium was then removed and cells were treated with
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FIGURE 3 | TICs of the 12 varied formulae (Vl-V12) of the HHCF in positive ionization mode.
fresh serum-free medium containing the test sample. After 5min,
30 ng/mL TNF-α and 30 ng/mL IFN-γ were added and the
cells were cultured for 24 h. After incubation, the medium was
collected and analyzed for CCL17 by ELISA according to the
manufacturer’s instruction (Fujita et al., 2011).
Cell Viability Assay
Cells were assessed for viability using the 3-(4,5-dimethylthizaol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. HaCaT
were seeded into a 96-well plate (200 µL per well of 2 × 104
cells/mL). After 24 h, the medium was replaced with serum-free
medium and cells were cultured for another 24 h. The medium
was then replaced with fresh medium containing the test sample.
After incubation for 24 h, the medium was removed and cells
were washed once with PBS and exposed to 0.5 mg/mL of MTT
for 3 h, in 5%CO2 at 37
◦C. Cells were then washed once with PBS
and the formazan precipitate was dissolved in DMSO (200 µL)
and the absorbance at 570 nm was measured using a microplate
reader. The percentage of cell viability was assessed as [mean
absorbance in tested wells]/[mean absorbance in control wells]×
100 (Qi et al., 2009). Assays were performed with two replicates
in three independent experiments (n= 3).
RESULTS AND DISCUSSION
HHCF and Its 12 Varied Formulae
The findings of this study underline the power of LC-MS-
based metabolite profiling, coupled with PLS-R to predict
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FIGURE 4 | TICs of the 12 varied formulae (Vl-V12) of the HHCF in negative ionization mode.
potential active components in CHM decoctions. The schematic
diagram of this study is shown in Figure 1. The PLS-
R model was developed based on the hypothesis that in
vitro activity of CHM decoctions varied with differences in
chemical components. To create the differences, 12 varied
formulae of the HHCF were developed by a uniform mixture
design approach. Uniform mixture design seeks to spread
the experimental points uniformly over the design space
and hence, facilitate the exploration of the relationship
between the in vitro biological response and the chemical
components with fewer number of runs when compared to
other experimental design methods such as factorial design
(Liang et al., 2001; Fang and Lin, 2003).
LC-MS/MS Metabolite Profiling
In previous publication (Chang et al., 2016), the chemical
compounds characterized in the HHCF in both positive
(Table 3A) and negative (Table 3B) modes were putatively
identified based on mass measurement and characteristic
fragment ions and by reference to the mass and MS/MS
spectra of reported compounds. The sources of these
compounds were defined by matching the retention times
and masses of ions detected in the HHCF decoction and
the single botanical drug decoctions, using an in-house
developed EXCEL template. Figures S1, S2 show the total
ion count (TIC) chromatograms of the single botanical drug
decoctions (i.e., DIC, KOC, PHE, RHE, SCU, and SOP) in
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FIGURE 5 | Effect of the HHCF (15, 30, 60, and 120 µ/ml) and its twelve varied formulae (Vl-V12; 30 and 60 µ/ml), SB202190 monohydrochloride hydrate (positive
control; 2.5 and 5µ) on TNF-a plus IFN-y-induced CCL17 production in HaCaT. Data are represented as mean ± standard error of three independent experiments (n
= 3). Statistical significance was determined using one-way analysis of variance with Dunnett’s multiple comparisons test. *p < 0.05 vs. TNF-a plus IFN-y treatment
alone.
positive and negative modes, respectively. The top 5 most
abundant compounds in the HHCF in positive ionization
mode are P14(allomatrine/ isomatrine/matrine/sophoridine),
P16 (allomatrine/isomatrine/matrine/sophoridine), P26
(phellodendrine), and P31 (berberine). The top 5 most abundant
compounds in the HHCF in negative ionization mode are N9
(gallic acid), N11(piscidic acid), N13 (catechin/epicatechin), N18
(catechin/epicatechin), N21(5-O-feruloylquinic acid), and N27
(lindleyin). The chemical structures of these compounds are
shown in Figure 2.
The TICs of the 12 varied formulae of the HHCF in
positive and negative ionization modes are shown in Figures 3,4,
respectively. The abundance of the characterized metabolites in
the HHCF and its 12 varied formulae decoctions are shown in
Table S1. These values of abundance were mean-centered and
scaled (Table S2) and were used as the independent variables for
building the PLS-R model.
Effects of the HHCF and Its 12 Varied
Formulae on CCL17 Production in HaCaT
Stimulated With TNF-α-Plus-IFN-γ
CCL17 have previously been demonstrated to be linked to
the pathogenesis of atopic dermatitis. They have been detected
in lesional AD skin but not in normal or non-lesional AD
tissue (Vestergaard et al., 2000; D’Ambrosio et al., 2002). In
addition, increased serum levels of CCL17 in individuals with
AD were correlated with disease severity (Kakinuma et al., 2001).
CCL17 are ligands for the CC chemokine receptor 4 (CCR4)
that are primarily expressed on Th2 lymphocytes (Saeki and
Tamaki, 2006). Hence, CCL17 contribute to the infiltration of
Th2 lymphocytes in skin inflammation sites. TheHCCF inhibited
the production of CCL17 in HaCaT stimulated with TNF-α-
plus-IFN-γ (Figure 5). To investigate which compounds in the
LC-MS metabolites profile of the HHCF were most likely to be
the contributors to the observed CCL17 inhibition, the effects of
the 12 varied formulae (V1-V12) of the HHCF against CCL17
production in HaCaT were also tested. The HHCF decoction
and its 12 varied formulae showed different degree of CCL17
inhibition in the HaCaT stimulated with TNF-α-plus-IFN-γ
(Figure 5). Results from the MTT assay demonstrated that
the decreased CCL17 levels were not due to any toxic effects
(Figure S3) of the samples on the cells.
The levels of CCL17 produced by TNF-α-plus-IFN-γ-
stimulated HaCaT after treatment with HHCF and its 12 varied
formulae (V1-V12) decoctions at a concentration of 60µg/ml
were used as the dependent variables for building the PLS-R
model. A lower absolute value of CCL17 represents a higher
inhibition effect, thus, a reciprocal was applied to the obtained
data. These data were then centered and scaled before model
building (Table S3).
Prediction of Potential Active Compounds
in HHCF Using PLS-R
Compounds in the LC-MS metabolites profile of the HHCF
that were most likely to be the contributors to the observed
CCL17 inhibition were predicted using PLS-R. PLS-R analysis
was used as (1) the number of dependent variables (response;
Table S3) was less than the number of independent variables (also
known as predictor variable; Table S2) and (2) this approach
uses linear combinations of the independent variables and avoids
the multicollinearity problem among the variables (Miller and
Miller, 2010). The number of latent variables for the PLS-R
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TABLE 4 | Relevance [regression coefficient (RC)] between the chemical
compounds putatively identified in the LC-MS profile of the HHCF decoction and
CCL17 response.
Ingredients PLS-RC Ingredients PLS-RC
P1 −0.0117 N1 −0.0655
P2 −0.0417 N2 0.0559
P3 0.0001 N3 0.0469
P4 0.0722 N4 −0.0379
P5 0.0071 N5 0.0724
P6 −0.1063 N6 0.0036
P7 −0.1002 N7 0.0763
P8 −0.0453 N8 0.0842
P9 −0.02 N9 0.0513
P10 −0.0445 N10 −0.026
P11 −0.0627 N11 −0.0415
P12 −0.0358 N12 0.0828
P13 0.0183 N13 0.0491
P14 0.0047 N14 −0.0203
P15 0.0205 N15 −0.0309
P16 0.0184 N16 0.0947
P17 0.0348 N17 −0.0623
P18 0.0066 N18 −0.0331
P19 0.005 N19 −0.0807
P20 −0.0046 N20 −0.0957
P21 −0.0263 N21 −0.0066
P22 −0.0186 N22 0.0726
P23 −0.0097 N23 0.0131
P24 0.0276 N24 −0.0403
P25 −0.0003 N25 −0.0759
P26 −0.0119 N26 −0.0036
P27 0.0069 N27 0.0685
P28 −0.0128 N28 −0.0059
P29 0.0016 N29 0.0273
P30 0.0149 N30 0.0742
P31 0.0823 N31 0.0765
N32 −0.0016
N33 −0.0114
N34 −0.0237
N35 0.0212
N36 −0.0144
N37 −0.0658
The top five contributors in the HHCF toward the CCL17 inhibition in the PLS-R model
were underlined.
analysis was selected based on the RMSECV value and the
percentage of variance explained by the PLS-R model. The
number of latent variables for the PLS-R analysis was selected
to be 9, representing the point of final drop in the prediction
error before the curve reaches a plateau (Figure S4). The 9
latent variables in the PLS-R model explained 100% of the
variation and 88.19% of the variance was explained by the
regressors (Table S4). Table 4 shows the regression coefficient of
the independent variables calculated using PLS-R analysis. The
positive and negative values of the regression coefficient (RC)
indicate a positive and negative contribution to the response
(i.e., CCL17 inhibition), respectively. Additionally, a higher
absolute value represents a larger contributory effect (Wang et al.,
2014). The top five contributors in the HHCF that promote
CCL17 inhibition in the PLS-R model were P31 (berberine), N8
(pyrogallol), N12(catechin dimers), N16 (4-(4′-hydroxyphenyl)-
2-butanone 4′-O-β-D-glucoside) and N31 (resveratrol 4′-O-
β-D-(6′′-O-galloyl) glucoside). Other glycosides of resveratrol
i.e., N30 (resveratrol-4′-O-β-D-(2′′-O-galloyl) glucoside) and
N22 (resveratrol-4′-O-β-D-glucoside OR resveratrol 3-O-β-
glucoside) in the HHCF are also important contributors to
the CCL17 inhibition, ranking 7th and 8th, respectively. Of
these, berberine, pyrogallol, catechin dimers, and resveratrol 3-
O-β-glucoside have shown anti-inflammatory effects in various
studies. Berberine was observed to inhibit the production of
proinflammatory cytokines interleukin (IL)-6 and chemokines
IL8 in HaCaT stimulated with sulfur mustard (Lang et al.,
2018) and their anti-inflammatory effects have been linked
to the inhibition of the nuclear factor-κB (NF-κB) signaling
pathway (Li et al., 2016). Catechin dimers (Andre et al., 2012)
and resveratrol 3-O-β-glucoside (Potapovich et al., 2011) have
also been shown to inhibit NF-κB activation in TNF- α-
stimulated-NF-κB/SEAP (Secreted alkaline phosphatase) HEK
293 cell lines and TNF-α-plus-IFN-γ-stimulated primary human
keratinocytes. Pyrogallol was shown to inhibit mRNA expression
of pro-inflammatory cytokines IL-6, chemokines (IL-8, CXCL1,
and CXCL3) and Intercellular adhesion molecules-1 (ICAM-
1) in cystic fibrosis bronchial epithelial cell lines (IB3-1
cells) stimulated with P. aeruginosa PAO1 (Nicolis et al.,
2008). Thus, these suggest the underlying mechanisms for
their respective potential anti-inflammatory roles in the HHCF
decoction.
CONCLUSION
In conclusion, an approach to predict potential active
components in a CHM formula was demonstrated by
correlating the LC-MS-based metabolite profiles of CHM
formulae to their anti-inflammatory activities based on
chemometrics. The results suggested that berberine, pyrogallol,
catechin dimers, 4-(4′-hydroxyphenyl)-2-butanone 4′-O-
β-D-glucoside and resveratrol 4′-O-β-D-(6′′-O-galloyl)
glucoside are the core anti-CCL17 bioactive ingredients
in the HHCF. Further evaluation and validation of the
activities of the predicted active components may support
the application of metabolite profiling of a CHM formula as
a quality control tool. This approach might also assist in the
optimization of CHM formulae and drug discovery. Though
the in vitro experimental studies were purely exploratory,
they also indicate potential areas for further research of
the HHCF as a botanical remedy for treatment of skin
inflammation.
The strategy employed in this research can facilitate a better
understanding of complex multiherbal preparations commonly
used not only in TCM but also in other local and traditional
medicines. While still time consuming it offers a strategy to
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clearly define the chemical basis of a complex preparation with
regards to the preparation’s pharmacological (or toxicological)
activity.
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